BACKGROUND: Cyberknife stereotactic radiosurgery is an emerging noninvasive technique for treating oligometastatic cancer. The aim of this study is to evaluate the efficacy and tolerability of cyberknife for the treatment of patients with lung metastases. MATERIALS AND METHODS: A total of 134 lung metastases in 95 patients were treated with cyberknife in the radiotherapy center of our hospital from March 2009 to March 2013. The number of lung metastases per patient ranged from one to four (single lesions in 63 patients, 66.3%). The average tumor volume was 14.6 cm(3) and the prescribed radiation dosage ranged from 30 to 60 Gy, fractionated one to five times with a 60% to 88% isodose line. The primary end point was local control (LC); secondary end points were survival and toxicity. RESULTS: The median follow-up was 17 months (ranging from 4 to 46 months). The 1-year LC rate was 97.6%, the 2-year LC rate was 90.6%, and the 3-year LC rate was 87.0%. The median survival time was 38.0 months and the median progression-free survival (PFS) time was 14.0 months. The 2-year PFS rate was 29.0% and the overall survival (OS) rate was 61.3%. No grade 4 or higher toxicity was encountered. CONCLUSIONS: Cyberknife is safe and effective treatment for patients with lung metastases.
BACKGROUND: Cyberknife stereotactic radiosurgery is an emerging noninvasive technique for treating oligometastatic cancer. The aim of this study is to evaluate the efficacy and tolerability of cyberknife for the treatment of patients with lung metastases. MATERIALS AND METHODS: A total of 134 lung metastases in 95 patients were treated with cyberknife in the radiotherapy center of our hospital from March 2009 to March 2013. The number of lung metastases per patient ranged from one to four (single lesions in 63 patients, 66.3%). The average tumor volume was 14.6 cm(3) and the prescribed radiation dosage ranged from 30 to 60 Gy, fractionated one to five times with a 60% to 88% isodose line. The primary end point was local control (LC); secondary end points were survival and toxicity. RESULTS: The median follow-up was 17 months (ranging from 4 to 46 months). The 1-year LC rate was 97.6%, the 2-year LC rate was 90.6%, and the 3-year LC rate was 87.0%. The median survival time was 38.0 months and the median progression-free survival (PFS) time was 14.0 months. The 2-year PFS rate was 29.0% and the overall survival (OS) rate was 61.3%. No grade 4 or higher toxicity was encountered. CONCLUSIONS: Cyberknife is safe and effective treatment for patients with lung metastases.
Entities:
Keywords:
Lung metastases; cyberknife; stereotactic body radiation therapy (SBRT)
Authors: Ronald C McGarry; Lech Papiez; Mark Williams; Tia Whitford; Robert D Timmerman Journal: Int J Radiat Oncol Biol Phys Date: 2005-08-22 Impact factor: 7.038
Authors: U Pastorino; M Buyse; G Friedel; R J Ginsberg; P Girard; P Goldstraw; M Johnston; P McCormack; H Pass; J B Putnam Journal: J Thorac Cardiovasc Surg Date: 1997-01 Impact factor: 5.209
Authors: Joseph K Salama; Michael D Hasselle; Steven J Chmura; Renuka Malik; Neil Mehta; Kamil M Yenice; Victoria M Villaflor; Walter M Stadler; Philip C Hoffman; Ezra E W Cohen; Philip P Connell; Daniel J Haraf; Everett E Vokes; Samuel Hellman; Ralph R Weichselbaum Journal: Cancer Date: 2011-10-21 Impact factor: 6.860
Authors: William T Brown; Xiaodong Wu; John F Fowler; Silvio García; Fahed Fayad; Beatriz E Amendola; Alberto de la Zerda; James G Schwade Journal: South Med J Date: 2008-04 Impact factor: 0.954
Authors: Kyle E Rusthoven; Brian D Kavanagh; Stuart H Burri; Changhu Chen; Higinia Cardenes; Mark A Chidel; Thomas J Pugh; Madeleine Kane; Laurie E Gaspar; Tracey E Schefter Journal: J Clin Oncol Date: 2009-03-02 Impact factor: 44.544
Authors: Matthew M Gestaut; Nitika Thawani; Sangroh Kim; Veera R Gutti; Sameer Jhavar; Niloyjyoti Deb; Andrew Morrow; Russell A Ward; Jason H Huang; Mehul Patel Journal: J Neurooncol Date: 2017-04-13 Impact factor: 4.130
Authors: Anthony Ricco; Joanne Davis; William Rate; Jun Yang; David Perry; John Pablo; David D'Ambrosio; Sanjeev Sharma; Srinath Sundararaman; James Kolker; Kimberly M Creach; Rachelle Lanciano Journal: Radiat Oncol Date: 2017-02-01 Impact factor: 3.481
Authors: Christopher H Chapman; Christopher McGuinness; Alexander R Gottschalk; Sue S Yom; Adam A Garsa; Mekhail Anwar; Steve E Braunstein; Atchar Sudhyadhom; Paul Keall; Martina Descovich Journal: J Appl Clin Med Phys Date: 2018-04-26 Impact factor: 2.102
Authors: Guillaume Virbel; David G Cox; Anne Olland; Pierre-Emmanuel Falcoz; Clara Le Fevre; Roland Schott; Delphine Antoni; Georges Noel Journal: Front Oncol Date: 2022-07-18 Impact factor: 5.738
Authors: Goda G Kalinauskaite; Ingeborg I Tinhofer; Markus M Kufeld; Anne A Kluge; Arne A Grün; Volker V Budach; Carolin C Senger; Carmen C Stromberger Journal: BMC Cancer Date: 2020-05-11 Impact factor: 4.430